Phenothiazines Enhance Macrophage Antibacterial Activity via ROS/Autophagy

Study Background and Research Question

Bacterial infections remain a major global health challenge, responsible for over ten million deaths annually. The rise of antimicrobial resistance (AMR) threatens the efficacy of conventional antibiotics, particularly against intracellular pathogens such as Salmonella enterica serovar Typhimurium, Shigella flexneri, Staphylococcus aureus, and Listeria monocytogenes. These pathogens evade antibiotic action by residing within host cells, complicating treatment and driving the search for new therapeutic strategies. Host-directed therapies (HDTs), which bolster the host immune response rather than targeting pathogens directly, have emerged as a promising approach. However, the mechanisms by which small molecules might enhance innate immune cell activity are not fully resolved. The recent open-access study by Qiu et al. (2025) addresses this gap by investigating the immunomodulatory effects of phenothiazines, including promethazine hydrochloride, on macrophage antibacterial functions.

Key Innovation from the Reference Study

The principal innovation of Qiu et al.'s research lies in elucidating how phenothiazines can be repurposed as host-acting compounds (HACs) to enhance macrophage-mediated bacterial clearance. Unlike antibiotics, these compounds do not directly affect bacterial viability, thereby minimizing selective pressure for resistance and preserving the gut microbiota. The study identifies two key mechanisms—induction of reactive oxygen species (ROS) and activation of autophagy—by which phenothiazines potentiate macrophage antibacterial activity. Notably, the study demonstrates that these effects are essential: pharmacologically blocking autophagy or scavenging ROS abrogates the phenothiazine-mediated antibacterial benefits (reference).

Methods and Experimental Design Insights

Qiu et al. employed a combination of in vitro and in vivo models to dissect the effects of phenothiazines on macrophage function. Key experimental approaches included:

• In vitro infection of macrophages with representative intracellular bacteria, followed by treatment with various phenothiazine derivatives, including promethazine HCl.
• Assessment of lysosomal activity, ROS generation (using DCFDA fluorescence), and autophagy (via LC3-II immunoblotting and puncta formation).
• Use of autophagy inhibitors (e.g., 3-methyladenine) and ROS scavengers (e.g., N-acetylcysteine) to probe mechanistic dependence.
• In vivo validation in murine models of S. Typhimurium infection, measuring bacterial burden, organ lesion scores, and inflammatory markers.

These methods enabled precise dissection of the cellular pathways involved in phenothiazine-induced antibacterial responses.

Protocol Parameters

• Phenothiazine treatment: Macrophages were pretreated with phenothiazines (e.g., promethazine hydrochloride) at micromolar concentrations for 1–2 hours prior to bacterial infection.
• Autophagy inhibition: 3-methyladenine (5 mM) was co-administered where indicated to block autophagy and confirm pathway dependence.
• ROS scavenging: N-acetylcysteine (5 mM) was used to neutralize ROS and assess its necessity for enhanced antibacterial activity.
• In vivo dosing: Perphenazine was administered to mice at established, non-toxic doses prior to S. Typhimurium challenge; similar protocols may be adapted for promethazine HCl in preclinical research, with dose adjustments based on solubility and pharmacokinetics (product information).
• Readouts: Bacterial CFU quantification, lysosomal and ROS assays, LC3 immunostaining, and histopathological scoring.

Core Findings and Why They Matter

The study established that phenothiazines significantly amplify the bactericidal capacity of macrophages by dual induction of ROS and autophagy. These effects were observed across multiple intracellular pathogens. The enhanced antibacterial response was mechanistically dependent on both ROS and autophagy pathways, as pharmacological inhibition of either process negated the observed benefits. In vivo, perphenazine reduced organ lesions and inflammation during S. Typhimurium infection, underscoring the translational potential of host-directed strategies (reference).

For the broader research community, these findings substantiate the use of phenothiazine derivatives such as promethazine HCl in immunology and inflammation studies, particularly for dissecting histaminergic signaling pathway inhibition and GPCR/G protein signaling dynamics.

Comparison with Existing Internal Articles

Several internal resources further contextualize the utility of promethazine hydrochloride in host-directed antibacterial research. For example, "Promethazine HCl: Histamine Antagonist for Immunology Research" highlights the compound’s ability to enhance macrophage antibacterial activity via ROS and autophagy induction, consistent with the reference study. Similarly, "Promethazine HCl: Empowering Host-Directed Antibacterial Assays" discusses optimizations for reproducible modulation of macrophage function, and "Promethazine HCl in Immunology: Enhanced Workflows and Insights" provides practical guidance for integrating ROS and autophagy endpoints into immunology protocols. Collectively, these resources reinforce the mechanistic and workflow implications of the current findings, and provide protocols and troubleshooting strategies for researchers working in cellular immunity and neuroscience receptor modulation.

Limitations and Transferability

While the study robustly demonstrates phenothiazine-induced enhancement of macrophage antibacterial activity, certain limitations warrant consideration. First, the majority of data derive from murine models and in vitro macrophage assays, which may not fully capture the complexity of human immune responses. Second, the study primarily examines perphenazine in vivo, with promethazine HCl and other derivatives tested mainly in cell-based systems. Dose-response relationships and long-term safety profiles in animal models remain to be established for promethazine HCl specifically. Finally, although phenothiazines act as broad histaminergic signaling pathway inhibitors and modulate GPCR signaling, off-target effects and potential immune modulation in other tissues should be systematically evaluated before translational application.

Why this cross-domain matters, maturity, and limitations

The cross-domain application of phenothiazines as both antipsychotic agents and immunomodulators illustrates the potential of drug repurposing for infectious disease research. However, maturity of this approach is currently limited to preclinical studies. Further research is needed to confirm efficacy and safety in human models, as well as to delineate the full spectrum of immunological effects in complex in vivo environments.

Research Support Resources

Researchers interested in host-directed antibacterial assays or in studying GPCR/G protein signaling, inflammation, or neuroscience receptor modulation can source Promethazine HCl (SKU B4784) from APExBIO. This phenothiazine derivative is available in high-purity powder or as a 10 mM DMSO solution, with robust solubility and stability profiles, supporting reproducible experimentation in immunology and cellular metabolism studies. For protocol optimization and mechanistic insights, consult related internal articles and recent literature to refine experimental design.